The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease

Massimo Volpe, Carmine Savoia, Paola De Paolis, Beata Ostrowska, David Tarasi, Speranza Rubattu

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The renin-angiotensin system (RAS) plays an important homeostatic role in BP regulation, water and salt balance, and tissue growth control under physiologic conditions. On the other hand, a pivotal involvement of the RAS in the pathophysiology of cardiovascular and renal disease is extensively supported by both basic and clinical evidence. In particular, it is today recognized that angiotensin II (AngII), the biologic effector of the RAS, may prompt a number of relevant structural and functional abnormalities through the activation of a complex of cellular effects mostly mediated via its binding with the AT1 subtype receptors. The key role of these AngII-linked mechanisms of disease is strongly corroborated by large interventional studies. In fact, pharmacologic interference with RAS activity, by both preventing AngII formation with angiotensin-converting enzyme inhibitors or antagonizing its binding to cell membrane receptors by selective antagonists, is associated with highly beneficial outcomes in major disease conditions (hypertension, diabetes, renal failure, heart failure, myocardial infarction, stroke, and others). This article briefly reviews the current views on the biologic organization of RAS evidence supporting a pathogenic role of the RAS activity in promoting cardiac, vascular, and renal disease, and finally provides the basis for considering inhibition of RAS activity a major target for therapeutic interventions in these conditions.

Original languageEnglish
JournalJournal of the American Society of Nephrology
Volume13
Issue numberSUPPL. 3
Publication statusPublished - Nov 1 2002

Fingerprint

Renin-Angiotensin System
Cardiovascular Diseases
Kidney
Angiotensin II
Therapeutics
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Renal Insufficiency
Heart Failure
Salts
Stroke
Myocardial Infarction
Cell Membrane
Hypertension
Water
Growth

ASJC Scopus subject areas

  • Nephrology

Cite this

The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. / Volpe, Massimo; Savoia, Carmine; De Paolis, Paola; Ostrowska, Beata; Tarasi, David; Rubattu, Speranza.

In: Journal of the American Society of Nephrology, Vol. 13, No. SUPPL. 3, 01.11.2002.

Research output: Contribution to journalArticle

@article{abb4c7bcaae54f3683eb678fec9693b3,
title = "The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease",
abstract = "The renin-angiotensin system (RAS) plays an important homeostatic role in BP regulation, water and salt balance, and tissue growth control under physiologic conditions. On the other hand, a pivotal involvement of the RAS in the pathophysiology of cardiovascular and renal disease is extensively supported by both basic and clinical evidence. In particular, it is today recognized that angiotensin II (AngII), the biologic effector of the RAS, may prompt a number of relevant structural and functional abnormalities through the activation of a complex of cellular effects mostly mediated via its binding with the AT1 subtype receptors. The key role of these AngII-linked mechanisms of disease is strongly corroborated by large interventional studies. In fact, pharmacologic interference with RAS activity, by both preventing AngII formation with angiotensin-converting enzyme inhibitors or antagonizing its binding to cell membrane receptors by selective antagonists, is associated with highly beneficial outcomes in major disease conditions (hypertension, diabetes, renal failure, heart failure, myocardial infarction, stroke, and others). This article briefly reviews the current views on the biologic organization of RAS evidence supporting a pathogenic role of the RAS activity in promoting cardiac, vascular, and renal disease, and finally provides the basis for considering inhibition of RAS activity a major target for therapeutic interventions in these conditions.",
author = "Massimo Volpe and Carmine Savoia and {De Paolis}, Paola and Beata Ostrowska and David Tarasi and Speranza Rubattu",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "13",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "SUPPL. 3",

}

TY - JOUR

T1 - The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease

AU - Volpe, Massimo

AU - Savoia, Carmine

AU - De Paolis, Paola

AU - Ostrowska, Beata

AU - Tarasi, David

AU - Rubattu, Speranza

PY - 2002/11/1

Y1 - 2002/11/1

N2 - The renin-angiotensin system (RAS) plays an important homeostatic role in BP regulation, water and salt balance, and tissue growth control under physiologic conditions. On the other hand, a pivotal involvement of the RAS in the pathophysiology of cardiovascular and renal disease is extensively supported by both basic and clinical evidence. In particular, it is today recognized that angiotensin II (AngII), the biologic effector of the RAS, may prompt a number of relevant structural and functional abnormalities through the activation of a complex of cellular effects mostly mediated via its binding with the AT1 subtype receptors. The key role of these AngII-linked mechanisms of disease is strongly corroborated by large interventional studies. In fact, pharmacologic interference with RAS activity, by both preventing AngII formation with angiotensin-converting enzyme inhibitors or antagonizing its binding to cell membrane receptors by selective antagonists, is associated with highly beneficial outcomes in major disease conditions (hypertension, diabetes, renal failure, heart failure, myocardial infarction, stroke, and others). This article briefly reviews the current views on the biologic organization of RAS evidence supporting a pathogenic role of the RAS activity in promoting cardiac, vascular, and renal disease, and finally provides the basis for considering inhibition of RAS activity a major target for therapeutic interventions in these conditions.

AB - The renin-angiotensin system (RAS) plays an important homeostatic role in BP regulation, water and salt balance, and tissue growth control under physiologic conditions. On the other hand, a pivotal involvement of the RAS in the pathophysiology of cardiovascular and renal disease is extensively supported by both basic and clinical evidence. In particular, it is today recognized that angiotensin II (AngII), the biologic effector of the RAS, may prompt a number of relevant structural and functional abnormalities through the activation of a complex of cellular effects mostly mediated via its binding with the AT1 subtype receptors. The key role of these AngII-linked mechanisms of disease is strongly corroborated by large interventional studies. In fact, pharmacologic interference with RAS activity, by both preventing AngII formation with angiotensin-converting enzyme inhibitors or antagonizing its binding to cell membrane receptors by selective antagonists, is associated with highly beneficial outcomes in major disease conditions (hypertension, diabetes, renal failure, heart failure, myocardial infarction, stroke, and others). This article briefly reviews the current views on the biologic organization of RAS evidence supporting a pathogenic role of the RAS activity in promoting cardiac, vascular, and renal disease, and finally provides the basis for considering inhibition of RAS activity a major target for therapeutic interventions in these conditions.

UR - http://www.scopus.com/inward/record.url?scp=0036840510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036840510&partnerID=8YFLogxK

M3 - Article

C2 - 12466309

AN - SCOPUS:0036840510

VL - 13

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - SUPPL. 3

ER -